SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Intellia Therapeutics Inc. (NTLA)

NTLA RSS Feed
Add NTLA Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 3/7/2017 2:18:44 PM - Followers: 8 - Board type: Free - Posts Today: 0

Intellia Therapeutics, Inc. is a United States-based genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. The Company's CRISPR/Cas9 technology edits diseased genes in the human body through a single treatment course. It focuses on the therapeutic applications of CRISPR/Cas9 genome editing. Its portfolio includes CRISPR/Cas9 platform technology, delivery technologies and nucleic acid modifications for human therapeutic use. The Company's CRISPR/Cas9 platform components include the guide ribonucleic acid (RNA) and the Cas9 nuclease (the genetic scissors). It has access to various delivery modalities specific to various in vivo and ex vivo approaches. The Company focuses on engineering ex vivo CRISPR/Cas9 cell therapies for chimeric antigen receptor T cell (CAR-T) and hematopoietic stem cell (HSC) applications. It also focuses on the use of in vivo Lipid Nanoparticle (LNP) delivery technology.
NTLA
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
SureTrader
NTLA News: Current Report Filing (8-k) 08/08/2017 04:31:36 PM
NTLA News: Quarterly Report (10-q) 08/01/2017 04:55:39 PM
NTLA News: Current Report Filing (8-k) 08/01/2017 07:37:14 AM
NTLA News:  Intellia Therapeutics Announces Second Quarter 2017 Financial Results 08/01/2017 07:30:00 AM
NTLA News: CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Appellate Brief Seeking Reversal of... 07/25/2017 05:00:00 PM
PostSubject
#2   Which of the big three is closest to redspinelpinktopaz 03/07/17 02:18:43 PM
#1   Took a starter here, CRISPR could do amazing things! rule_rationale 05/10/16 11:00:34 AM
PostSubject